Selexis CHO Cells in Suspension-1

About Us

We are visionaries of innovation and pioneers of change! We understand the complexities of the CHO cell better than anyone and, as such, we give our partners an advantage as they seek to be first-in-human (FIH) and first-to-market (FTM) with their biologic medicines and vaccines.

At our core, Selexis is a company of dreamers and adventurers — thoughtful risk-takers willing to travel the difficult road to empower innovation in drug development and ultimately transform the care of and prospects for millions of patients who suffer from life-threatening diseases. Our journey began in 2001 when our Company was formed behind an ambitious vision: to change how biologic drugs are developed.


Harnessing our breakthrough technologies and building a team of the best and brightest professionals — unafraid of pushing the limits on what our technology can do — Selexis has become the scientific pioneer and global leader in mammalian cell line generation. Today, the name Selexis is synonymous with excellence in our field.

Our global leadership position was born from our initial vision and commitment to bring change to an industry that continually requires unrelenting urgency and a bold pace of innovation. Patients’ lives depend on it. They can’t wait, and neither will we.

Continued advances in technologies and methods for protein expression are critical for further development of medicines that are based on recombinant proteins, such as monoclonal antibodies and difficult-to-express proteins, including Fc-fusion, bi-specific monoclonal antibodies, and novel scaffolds. This is where our expertise truly makes a difference.

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for nearly two decades. Our proprietary SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization. The strength and utility of SUREtechnology is evidenced through results from our 2019 customer survey. Ninety-three percent of respondents said they would work with Selexis again and would recommend Selexis.



Continually provide breakthrough technologies fundamentally impacting and improving drug discovery, drug development, and biopharmaceutical manufacturing



Advancing innovation, safety and new therapies impacting patients' quality of life



Rapid development and engineering of clonal mammalian research cell banks (RCBs)

Full research cell bank documentation with genome characterization, traceability, and “clonality” reports



  • Founded in 2001
  • GLOBALLY TRUSTED: Partners in more than 42 countries, representing the complete spectrum of life sciences—from research laboratories and biotech startups to big pharma
  • VALIDATED: There are more than 160 Selexis-generated research cell banks being used for clinical programs and 10 marketed products in cancer, autoimmune/inflammatory and metabolic/genetic disorders
  • FOCUS ON INNOVATION: 210 granted patents that cover innovations in genetic elements, procedures/ transfection, cell line engineering, and devices related to cell line development and protein expression
  • RAPID: Can move from transfection to banking of a high-expressing and stable production-ready research cell bank in as little as 8-12 weeks depending on cloaning strategy.


Selexis is the leader in cell line development


  • Advanced gene transfection technology and procedure

  • Proprietary CHO-K1 cell line

  • Defined media and feed strategies

  • Product and cell line analytics/characterization